OKYO Pharma Ltd
OKYO · XNASCIK 1849296fmd_0P4TCJPDPHG0A28MWCNG7ZX42PManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Apr 01, 2019 to Mar 31, 2026, 7 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Research and development | 1 | 0 | 2 | 6 | 8 | 2 |
| Total operating expenses | 2 | 3 | 6 | 13 | 16 | 7 |
| Interest expense | 0 | 0 | – | 0 | 1 | 1 |
| Income before taxes | (2) | (3) | (6) | (13) | (17) | (8) |
| Income tax expense | 0 | 0 | 1 | 0 | (0) | 3 |
| Net income from continuing operations | (2) | (3) | (7) | (13) | (17) | (11) |
| Net income | (2) | (3) | (5) | (13) | (17) | (5) |
| Net income to common shareholders | (2) | (3) | (5) | (13) | (17) | (8) |